03.08.2023 - Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with dosing to begin this quarter AB-729 (imdusiran), in combination with pegylated interferon alfa-2a, in a Phase .
WARMINSTER, Pa., July 12, 2023 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target.
Arbutus Appoints Two New Executives streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Treatment was generally well tolerated with continued HBsAg declines in some patients WARMINSTER, Pa., June 21, 2023 Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company. | June 21, 2023
Evaluating safety and efficacy of combining AB-729, VTP-300, nucleoside analogues and nivolumab WARMINSTER, Pa., June 21, 2023 Arbutus Biopharma Corporation , a clinical-stage. | June 21, 2023